Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: schellens jh. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.
Schoemaker NE, Rosing H, Jansen S, Schöffski P, Rizzo J, Schellens JH, Beijnen JH. Schoemaker NE, et al. Among authors: schellens jh. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 5;775(2):231-7. doi: 10.1016/s1570-0232(02)00294-5. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12113990
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E, ten Bokkel Huinink WW, Taïeb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH; European Organization for the Research and Treatment of Cancer Early Clinical Study Group. Raymond E, et al. Among authors: schellens jh. J Clin Oncol. 2002 Aug 15;20(16):3508-21. doi: 10.1200/JCO.2002.09.030. J Clin Oncol. 2002. PMID: 12177112 Clinical Trial.
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schellens JH, ten Bokkel Huinink WW. Schoemaker NE, et al. Among authors: schellens jh. Br J Cancer. 2002 Sep 9;87(6):608-14. doi: 10.1038/sj.bjc.6600516. Br J Cancer. 2002. PMID: 12237769 Free PMC article. Clinical Trial.
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. Among authors: schellens jh. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH; Early Clinical Studies Group of the EORTC and NDDO Oncology. van Kesteren C, et al. Among authors: schellens jh. Br J Clin Pharmacol. 2002 Nov;54(5):463-71. doi: 10.1046/j.1365-2125.2002.01684.x. Br J Clin Pharmacol. 2002. PMID: 12445024 Free PMC article. Clinical Trial.
891 results